EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The ctDNA Paradigm: Dynamic Observation, Quantitative Analysis, and Interpretive Limits in Precision Oncology

Massimiliano Chetta iD, Nenad Bukvic iD, Alessandra Rosati iD

Genes · 30.06.2026 · 17 (7) · 754

DOI: 10.3390/genes17070754 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 30.06.2026. Verfasst von Massimiliano Chetta und 2 weiteren Autor:innen. Beteiligte Einrichtung: Complex Operative Unit of Pathological Anatomy and Molecular Diagnostics, San Giovanni di Dio Ruggi d'Aragona, Schola Medica Salernitana, Largo Città…. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Precision Medicine, Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Circulating tumor DNA (ctDNA) was initially conceived as a minimally invasive surrogate for interrogating cancer biology; however, three decades of evidence have demonstrated that plasma is not a passive reservoir of tumor-derived material, but rather a dynamic and biologically heterogeneous milieu in which multiple competing genomic signals coexist. This review explores the level of interpretive rigor required to translate ctDNA detection into clinically actionable precision oncology. Clonal hematopoiesis of indeterminate potential (CHIP) is discussed not as an occasional confounder, but as an intrinsic source of biological background noise, underscoring the critical importance of matched leukocyte sequencing to discriminate tumor-derived alterations from hematopoietic variants, particularly in older individuals and in patients previously exposed to cytotoxic therapies. The widespread assumption that variant allele frequency (VAF) directly reflects tumor burden is critically re-evaluated through the mathematical relationships linking VAF to tumor fraction, local copy-number architecture, and mutation multiplicity. Within this framework, estimation of cancer cell fraction (CCF) and probabilistic discrimination between clonal and subclonal events are examined, including the emergence of reversion mutations as molecular evidence of therapy-driven evolutionary adaptation. The review also addresses the central paradox of ultra-sensitive sequencing technologies: although unique molecular identifiers and duplex sequencing can extend analytical sensitivity below 0.01% VAF, sensitivity in the absence of contextual specificity risks conflating technical artifacts and biologically insignificant alterations with clinically meaningful disease. Equal emphasis is placed on pre-analytical variables, highlighting how sample collection, stabilization, and processing protocols define the upper limit of downstream analytical reliability. Beyond single-nucleotide variants, fragmentomic and methylation-based approaches are presented as complementary orthogonal dimensions capable of revealing tumor-associated signals even when mutational evidence is limited or absent. Longitudinal ctDNA assessment is argued to provide substantially greater biological and clinical insight than isolated static measurements, while robust clinical reporting is shown to depend on transparent disclosure of assay limitations, residual uncertainty related to CHIP, and structured bidirectional communication between molecular laboratories and treating clinicians. Ultimately, the transition from a biomarker-centered model toward an integrated systems-based framework, combining genomics, epigenomics, fragmentomics, and evolutionary modeling, emerges as the defining challenge for the next generation of liquid biopsy in precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAPrecision MedicineNeoplasmsBiomarkers, TumorHumansMutationGene Frequency

Stichwörter der Autor:innen

cancer cell fractionclonal hematopoiesisctDNAfragmentomicsliquid biopsyvariant allele frequency

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Complex Operative Unit of Pathological Anatomy and Molecular Diagnostics, San Giovanni di Dio Ruggi d'Aragona, Schola Medica Salernitana, Largo Città di Ippocrate, 84131 Salerno, Italy.
  • U.O.C. Genetica Medica, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, 70124 Bari, Italy.
  • Department of Medicine, Surgery and Dentistry, Schola Medica Salernitana, University of Salerno, 84081 Baronissi, Italy.

ORCID-Profile: Massimiliano Chetta, Nenad Bukvic, Alessandra Rosati

Zitieren

APA

Chetta, M., Bukvic, N., & Rosati, A. (2026). The ctDNA Paradigm: Dynamic Observation, Quantitative Analysis, and Interpretive Limits in Precision Oncology. Genes, 17(7), 754. https://doi.org/10.3390/genes17070754

Vancouver

Chetta M, Bukvic N, Rosati A. The ctDNA Paradigm: Dynamic Observation, Quantitative Analysis, and Interpretive Limits in Precision Oncology. Genes. 2026;17(7):754. doi:10.3390/genes17070754

BibTeX
@article{Chetta2026,
  author = {Chetta, Massimiliano and Bukvic, Nenad and Rosati, Alessandra},
  title = {The ctDNA Paradigm: Dynamic Observation, Quantitative Analysis, and Interpretive Limits in Precision Oncology},
  journal = {Genes},
  year = {2026},
  volume = {17},
  number = {7},
  pages = {754},
  doi = {10.3390/genes17070754}
}
Kostenlos starten →